Phenotypes associated with this allele

• Allele Symbol: Bpgm^m1Pgrs
• Allele Name: mutation 1, Philippe Gros
• Allele ID: MGI:6506869
• Summary: 2 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
hm1	Bpgm^m1Pgrs/Bpgm^m1Pgrs	involves: A/J	MGI:6507033
hm2	Bpgm^m1Pgrs/Bpgm^m1Pgrs	involves: C57BL/6 * C57BL/10J	MGI:6507032

Genotype
MGI:6507033

hm1

• Allelic Composition: Bpgm^m1Pgrs/Bpgm^m1Pgrs
• Genetic Background: involves: A/J

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

immune system

decreased susceptibility to parasitic infection induced morbidity/mortality ( J:301620 )

• reduced susceptibility to experimentally induced severe malarial aneamia (SMA) by P. chabaudi AS (PcA): mice more than 80% survive beyond 20 days post infection (20d p.i.) (vs 100% mortality by d12 in WT)

• reduced susceptibility to PcA-induced SMA: lower peak blood parasitemia at 10d p.i. and progressive decrease after that

mortality/aging

decreased susceptibility to parasitic infection induced morbidity/mortality ( J:301620 )

• reduced susceptibility to experimentally induced severe malarial aneamia (SMA) by P. chabaudi AS (PcA): mice more than 80% survive beyond 20 days post infection (20d p.i.) (vs 100% mortality by d12 in WT)

• reduced susceptibility to PcA-induced SMA: lower peak blood parasitemia at 10d p.i. and progressive decrease after that

Genotype
MGI:6507032

hm2

• Allelic Composition: Bpgm^m1Pgrs/Bpgm^m1Pgrs
• Genetic Background: involves: C57BL/6 * C57BL/10J

hematopoietic system

enlarged spleen ( J:301620 )

• splenomegaly at day 6 post infection (d6 p.i.) with P. berghei ANKA (PbA)

• splenomegaly at day 10 post infection (d10 p.i.) with P. chabaudi AS (PcA)

• no splenomegaly in uninfected mice

abnormal erythropoiesis ( J:301620 )

• higher increase in erythropoiesis at day 6 post infection (d6 p.i.) with P. berghei ANKA (PbA)

• higher increase in erythroblast number in bone marrow and spleen at day 6 post infection (d6 p.i.) with P. berghei ANKA (PbA)

• 2x increase in erythroid cells in spleen at d10 p.i. with P. chabaudi AS (PcA) compared to WT

• normal erythroid cell numbers in bone marrow at d10 p.i. with P. chabaudi AS (PcA)

abnormal stress erythropoiesis ( J:301620 )

• increased erythropoietic activity in spleen after phenylhydrazine (PHZ) administration

increased erythroblast number ( J:301620 )

• higher increase in erythroblast number in bone marrow and spleen at day 6 post infection (d6 p.i.) with P. berghei ANKA (PbA)

• 2x increase in erythroid cells in spleen at d10 p.i. with P. chabaudi AS (PcA) compared to WT

• normal erythroid cell numbers in bone marrow at d10 p.i. with P. chabaudi AS (PcA)

polycythemia ( J:301620 )

increased hematocrit ( J:301620 )

increased hemoglobin content ( J:301620 )

increased mean corpuscular hemoglobin ( J:301620 )

macrocytosis ( J:301620 )

abnormal reticulocyte cell number ( J:301620 )

• increased number of reticulocytes in bone marrow and spleen

• higher increase in reticulocyte number in bone marrow and spleen at day 6 post infection (d6 p.i.) with P. berghei ANKA (PbA)

reticulocytosis ( J:301620 )

• increased percentage of circulating reticulocytes at day 6 post infection (d6 p.i.) with P. berghei ANKA (PbA)

• normal percentage of circulating reticulocytes in uninfected mice

abnormal erythrocyte physiology ( J:301620 )

• decreased energy metabolism in red blood cells with very low ATP/GTP pools

homeostasis/metabolism

increased blood oxygen capacity ( J:301620 )

increased circulating erythropoietin level ( J:301620 )

mortality/aging

decreased susceptibility to parasitic infection induced morbidity/mortality ( J:301620 )

• reduced susceptibility to experimentally induced cerebral malaria (ECM) by P. berghei ANKA (PbA): mice more than 50% survive beyond 10 days post infection (10d p.i.) and display reduced cellular extravasation and CD45+ myeloid and lymphoid cell infiltration of brain at d6 p.i.

• reduced susceptibility to PbA-induced ECM: reduction in blood parasitemia at d4, d5 and d6 p.i.

• reduced proportion of late-stage Plasmodium parasites in red blood cells after infection with P. berghei ANKA (PbA) or P. chabaudi AS (PcA)

growth/size/body

enlarged spleen ( J:301620 )

• splenomegaly at day 6 post infection (d6 p.i.) with P. berghei ANKA (PbA)

• splenomegaly at day 10 post infection (d10 p.i.) with P. chabaudi AS (PcA)

• no splenomegaly in uninfected mice

immune system

immune system phenotype ( J:301620 )

N • no splenomegaly

N • normal immunocyte compartments in bone marrow and spleen

enlarged spleen ( J:301620 )

• splenomegaly at day 6 post infection (d6 p.i.) with P. berghei ANKA (PbA)

• splenomegaly at day 10 post infection (d10 p.i.) with P. chabaudi AS (PcA)

• no splenomegaly in uninfected mice

decreased susceptibility to parasitic infection induced morbidity/mortality ( J:301620 )

• reduced susceptibility to experimentally induced cerebral malaria (ECM) by P. berghei ANKA (PbA): mice more than 50% survive beyond 10 days post infection (10d p.i.) and display reduced cellular extravasation and CD45+ myeloid and lymphoid cell infiltration of brain at d6 p.i.

• reduced susceptibility to PbA-induced ECM: reduction in blood parasitemia at d4, d5 and d6 p.i.

• reduced proportion of late-stage Plasmodium parasites in red blood cells after infection with P. berghei ANKA (PbA) or P. chabaudi AS (PcA)